$251.03
2.350.94%
At Close: -
$251.03
00.00%
After Hours: 4:38 PM EDT
15 minutes delayed
want to know what
the Bulls & Bears Say?
Alnylam Pharmaceuticals (NASDAQ:ALNY) 주식, 분석가 평가, 목표 가격, 예측
Alnylam Pharmaceuticals Inc의 합의된 목표 주가는 100개의 최신 애널리스트 평가를 살펴보고 설정되었습니다. 마지막 3개의 애널리스트 평가는 7월 3, 2024, 7월 1, 2024 및 6월 28, 2024에 JP Morgan, Cantor Fitzgerald 및 UBS에서 발표되었습니다. JP Morgan, Cantor Fitzgerald 및 UBS 사이의 평균 목표 주가는 $228.67로, 이러한 3개의 애널리스트 평가에서 Alnylam Pharmaceuticals Inc에 대한 암시된 -8.91% downside가 있습니다.
추천을 하는 애널리스트 회사들1
JP Morgan
Cantor Fitzgerald
UBS
RBC Capital
Stifel
1애널리스트 평가로부터 계산됨
Alnylam Pharmaceuticals에 대한 애널리스트 평점
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/03/2024 | Buy Now | -1.21% | JP Morgan | Jessica Fye | $160 → $248 | Maintains | Neutral | Get Alert |
| 07/01/2024 | Buy Now | -40.25% | Cantor Fitzgerald | Olivia Brayer | $150 → $150 | Reiterates | Neutral → Neutral | Get Alert |
| 06/28/2024 | Buy Now | 14.73% | UBS | Eliana Merle | $253 → $288 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | 5.57% | RBC Capital | Luca Issi | $250 → $265 | Maintains | Outperform | Get Alert |
| 06/27/2024 | Buy Now | 17.52% | Stifel | Paul Matteis | $215 → $295 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 15.92% | Citigroup | David Lebovitz | $227 → $291 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 17.52% | B of A Securities | — | $248 → $295 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | -36.66% | Leerink Partners | — | $138 → $159 | Maintains | Market Perform | Get Alert |
| 06/25/2024 | Buy Now | 12.34% | TD Cowen | Ritu Baral | $260 → $282 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 3.57% | Evercore ISI Group | Liisa Bayko | $210 → $260 | Maintains | Outperform | Get Alert |
| 06/25/2024 | Buy Now | 15.92% | Barclays | Gena Wang | $236 → $291 | Maintains | Overweight | Get Alert |
| 06/25/2024 | Buy Now | -0.41% | RBC Capital | Luca Issi | $235 → $250 | Maintains | Outperform | Get Alert |
| 06/25/2024 | Buy Now | -17.54% | Wells Fargo | Tiago Fauth | $161 → $207 | Maintains | Equal-Weight | Get Alert |
| 06/25/2024 | Buy Now | -0.41% | Morgan Stanley | Michael Ulz | $164 → $250 | Maintains | Equal-Weight | Get Alert |
| 06/24/2024 | Buy Now | 9.55% | Needham | Joseph Stringer | $200 → $275 | Maintains | Buy | Get Alert |
| 06/24/2024 | Buy Now | 59.34% | HC Wainwright & Co. | Patrick Trucchio | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 06/24/2024 | Buy Now | -6.78% | BMO Capital | Kostas Biliouris | $234 → $234 | Maintains | Outperform | Get Alert |
| 06/21/2024 | Buy Now | 12.74% | Canaccord Genuity | Whitney Ijem | $283 → $283 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | 59.34% | HC Wainwright & Co. | Patrick Trucchio | $395 → $400 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | -10.37% | Chardan Capital | Keay Nakae | $225 → $225 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | -20.33% | Needham | Joseph Stringer | → $200 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | -6.78% | BMO Capital | Kostas Biliouris | $234 → $234 | Maintains | Outperform | Get Alert |
| 03/05/2024 | Buy Now | 57.35% | HC Wainwright & Co. | Patrick Trucchio | → $395 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | Buy Now | -40.25% | Cantor Fitzgerald | Olivia Brayer | $165 → $150 | Maintains | Neutral | Get Alert |
| 02/21/2024 | Buy Now | -6.39% | RBC Capital | Luca Issi | → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2024 | Buy Now | -34.27% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 02/20/2024 | Buy Now | -6.39% | RBC Capital | Luca Issi | → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/16/2024 | Buy Now | -35.86% | Wells Fargo | Tiago Fauth | $171 → $161 | Maintains | Equal-Weight | Get Alert |
| 02/16/2024 | Buy Now | -9.57% | Citigroup | David Lebovitz | $237 → $227 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | -6.39% | RBC Capital | Luca Issi | → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/16/2024 | Buy Now | -10.37% | Chardan Capital | Keay Nakae | $250 → $225 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | -31.08% | Goldman Sachs | Salveen Richter | $230 → $173 | Downgrade | Buy → Neutral | Get Alert |
| 02/15/2024 | Buy Now | -20.33% | Needham | Joseph Stringer | → $200 | Reiterates | Buy → Buy | Get Alert |
| 02/15/2024 | Buy Now | -34.27% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 02/15/2024 | Buy Now | — | Wolfe Research | Andy Chen | — | Initiates | → Peer Perform | Get Alert |
| 02/14/2024 | Buy Now | -6.39% | RBC Capital | Luca Issi | → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/13/2024 | Buy Now | -29.89% | Morgan Stanley | Michael Ulz | $184 → $176 | Maintains | Equal-Weight | Get Alert |
| 02/12/2024 | Buy Now | -34.27% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 02/01/2024 | Buy Now | -32.28% | JP Morgan | Jessica Fung | $150 → $170 | Maintains | Neutral | Get Alert |
| 01/22/2024 | Buy Now | -34.27% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 01/18/2024 | Buy Now | -34.27% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 12/15/2023 | Buy Now | 57.35% | HC Wainwright & Co. | Patrick Trucchio | → $395 | Reiterates | Buy → Buy | Get Alert |
| 12/14/2023 | Buy Now | -34.27% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 12/14/2023 | Buy Now | -13.56% | Piper Sandler | Edward Tenthoff | $210 → $217 | Maintains | Overweight | Get Alert |
| 12/08/2023 | Buy Now | -31.88% | Wells Fargo | Tiago Fauth | → $171 | Initiates | → Equal-Weight | Get Alert |
| 11/15/2023 | Buy Now | 57.35% | HC Wainwright & Co. | Patrick Trucchio | → $395 | Reiterates | Buy → Buy | Get Alert |
| 11/03/2023 | Buy Now | -8.38% | RBC Capital | Luca Issi | $235 → $230 | Maintains | Outperform | Get Alert |
| 11/03/2023 | Buy Now | -27.1% | Morgan Stanley | Michael Ulz | $175 → $183 | Maintains | Equal-Weight | Get Alert |
| 10/16/2023 | Buy Now | -32.28% | Cantor Fitzgerald | Olivia Brayer | $190 → $170 | Maintains | Neutral | Get Alert |
| 10/11/2023 | Buy Now | — | Oppenheimer | Leland Gershell | — | Downgrade | Outperform → Perform | Get Alert |
| 10/11/2023 | Buy Now | -6.39% | RBC Capital | Luca Issi | $270 → $235 | Maintains | Outperform | Get Alert |
| 10/11/2023 | Buy Now | 57.35% | HC Wainwright & Co. | Patrick Trucchio | $405 → $395 | Maintains | Buy | Get Alert |
| 10/10/2023 | Buy Now | -30.29% | Morgan Stanley | Michael Ulz | $210 → $175 | Maintains | Equal-Weight | Get Alert |
| 10/10/2023 | Buy Now | -6.78% | BMO Capital | Kostas Biliouris | $250 → $234 | Maintains | Outperform | Get Alert |
| 10/10/2023 | Buy Now | -7.18% | Citigroup | David Lebovitz | $266 → $233 | Maintains | Buy | Get Alert |
| 10/09/2023 | Buy Now | -20.33% | Needham | Joseph Stringer | $240 → $200 | Maintains | Buy | Get Alert |
| 10/06/2023 | Buy Now | 7.56% | RBC Capital | Luca Issi | → $270 | Reiterates | Outperform → Outperform | Get Alert |
| 09/29/2023 | Buy Now | -17.14% | Raymond James | Gary Nachman | → $208 | Initiates | → Outperform | Get Alert |
| 09/18/2023 | Buy Now | 61.34% | HC Wainwright & Co. | Patrick Trucchio | → $405 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | Buy Now | -4.39% | Stifel | Paul Matteis | → $240 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | Buy Now | -24.31% | Cantor Fitzgerald | Olivia Brayer | → $190 | Reiterates | Neutral → Neutral | Get Alert |
| 09/14/2023 | Buy Now | -4.39% | Needham | Joseph Stringer | → $240 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | Buy Now | 7.56% | RBC Capital | Luca Issi | → $270 | Reiterates | Outperform → Outperform | Get Alert |
| 09/12/2023 | Buy Now | -4.39% | Needham | Joseph Stringer | → $240 | Reiterates | Buy → Buy | Get Alert |
| 08/28/2023 | Buy Now | 7.56% | RBC Capital | Luca Issi | → $270 | Reiterates | Outperform → Outperform | Get Alert |
| 08/18/2023 | Buy Now | 7.56% | RBC Capital | Luca Issi | → $270 | Reiterates | Outperform → Outperform | Get Alert |
| 08/16/2023 | Buy Now | -24.31% | Cantor Fitzgerald | Olivia Brayer | → $190 | Reiterates | Neutral → Neutral | Get Alert |
| 08/08/2023 | Buy Now | -0.41% | Chardan Capital | Keay Nakae | → $250 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | 61.34% | HC Wainwright & Co. | Patrick Trucchio | → $405 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | Buy Now | -16.34% | Morgan Stanley | Michael Ulz | $210 → $210 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 08/04/2023 | Buy Now | 7.56% | RBC Capital | Luca Issi | → $270 | Reiterates | Outperform → Outperform | Get Alert |
| 08/04/2023 | Buy Now | 5.96% | Citigroup | David Lebovitz | $265 → $266 | Maintains | Buy | Get Alert |
| 08/04/2023 | Buy Now | -4.39% | Needham | Joseph Stringer | → $240 | Reiterates | Buy → Buy | Get Alert |
| 07/25/2023 | Buy Now | 7.56% | RBC Capital | Luca Issi | $275 → $270 | Maintains | Outperform | Get Alert |
| 07/25/2023 | Buy Now | 61.34% | HC Wainwright & Co. | Patrick Trucchio | $415 → $405 | Maintains | Buy | Get Alert |
| 07/13/2023 | Buy Now | -20.33% | Cantor Fitzgerald | Olivia Brayer | → $200 | Reiterates | Neutral → Neutral | Get Alert |
| 07/12/2023 | Buy Now | -20.33% | Cantor Fitzgerald | Olivia Brayer | → $200 | Reiterates | Neutral → Neutral | Get Alert |
| 06/23/2023 | Buy Now | -20.33% | Cantor Fitzgerald | Olivia Brayer | $200 → $200 | Reiterates | Neutral → Neutral | Get Alert |
| 06/22/2023 | Buy Now | -20.33% | Cantor Fitzgerald | Olivia Brayer | → $200 | Reiterates | Neutral → Neutral | Get Alert |
| 05/31/2023 | Buy Now | 9.55% | RBC Capital | Luca Issi | → $275 | Reiterates | Outperform → Outperform | Get Alert |
| 05/05/2023 | Buy Now | -0.41% | BMO Capital | Kostas Biliouris | $200 → $250 | Upgrade | Market Perform → Outperform | Get Alert |
| 05/05/2023 | Buy Now | -4.39% | Needham | Joseph Stringer | → $240 | Reiterates | → Buy | Get Alert |
| 04/27/2023 | Buy Now | -4.39% | Needham | Joseph Stringer | → $240 | Reiterates | → Buy | Get Alert |
| 04/27/2023 | Buy Now | 65.32% | HC Wainwright & Co. | Patrick Trucchio | → $415 | Reiterates | → Buy | Get Alert |
| 04/26/2023 | Buy Now | -12.36% | SMBC Nikko | David Hoang | → $220 | Initiates | → Neutral | Get Alert |
| 04/04/2023 | Buy Now | -16.34% | Morgan Stanley | Michael Ulz | $205 → $210 | Maintains | Equal-Weight | Get Alert |
| 03/21/2023 | Buy Now | -3.2% | Bernstein | William Pickering | → $243 | Initiates | → Outperform | Get Alert |
| 03/03/2023 | Buy Now | -21.92% | JP Morgan | Jessica Fung | $200 → $196 | Maintains | Neutral | Get Alert |
| 03/03/2023 | Buy Now | 65.32% | HC Wainwright & Co. | Patrick Trucchio | → $415 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | 15.92% | Canaccord Genuity | Whitney Ijem | $310 → $291 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | -18.34% | Morgan Stanley | Michael Ulz | $210 → $205 | Maintains | Equal-Weight | Get Alert |
| 02/24/2023 | Buy Now | 5.57% | Citigroup | David Lebovitz | $270 → $265 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | -0.81% | Oppenheimer | Leland Gershell | $256 → $249 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | -0.41% | Chardan Capital | Keay Nakae | → $250 | Reiterates | → Buy | Get Alert |
| 02/24/2023 | Buy Now | 21.1% | EF Hutton | Michael King | → $304 | Reiterates | → Buy | Get Alert |
| 02/24/2023 | Buy Now | -4.39% | Needham | Joseph Stringer | → $240 | Reiterates | → Buy | Get Alert |
| 02/21/2023 | Buy Now | 21.1% | EF Hutton | Michael King | → $304 | Initiates | → Buy | Get Alert |
| 01/23/2023 | Buy Now | -43.03% | SVB Leerink | Mani Foroohar | $144 → $143 | Maintains | Market Perform | Get Alert |
| 01/18/2023 | Buy Now | 23.49% | Canaccord Genuity | Whitney Ijem | → $310 | Initiates | → Buy | Get Alert |
| 12/16/2022 | Buy Now | 0.78% | Piper Sandler | Edward Tenthoff | $226 → $253 | Maintains | Overweight | Get Alert |
FAQ
Alnylam Pharmaceuticals (ALNY) 주식의 목표가는 얼마인가요?
Alnylam Pharmaceuticals (NASDAQ:ALNY)의 최신 목표 주가는 7월 3, 2024에 JP Morgan에 의해 보고되었습니다. 이 애널리스트 기관은 $248.00에 대한 가격 목표를 설정했으며, 12개월 이내에 ALNY이(가) fall될 것으로 예상합니다 (가능한 -1.21% downside). 지난 1년간 77개의 애널리스트 기관이 평가를 보고했습니다.
Alnylam Pharmaceuticals (ALNY)에 대한 가장 최근의 애널리스트 평가는 무엇인가요?
Alnylam Pharmaceuticals (NASDAQ:ALNY)에 대한 최신 애널리스트 평가는 JP Morgan에 의해 제공되었으며, Alnylam Pharmaceuticals은(는) neutral 평가를 유지했다합니다.
Alnylam Pharmaceuticals (ALNY)에 대한 마지막 업그레이드는 언제 있었나요?
Alnylam Pharmaceuticals Inc에 대한 마지막 업그레이드는 5월 5, 2023에 발생했습니다. 이 때 BMO Capital는 $250로 가격 목표를 올렸습니다. BMO Capital는 이전에 Alnylam Pharmaceuticals Inc에 대해 a market perform를 가지고 있었습니다.
Alnylam Pharmaceuticals (ALNY)에 대한 마지막 다운그레이드는 언제 있었나요?
Alnylam Pharmaceuticals Inc에 대한 마지막 다운그레이드는 2월 16, 2024에 발생했습니다. 이 때 Goldman Sachs가 Alnylam Pharmaceuticals Inc에 대해 가격 목표를 $230에서 $173로 변경했습니다.
Alnylam Pharmaceuticals (ALNY)에 대한 다음 애널리스트 평가는 언제 게시 또는 업데이트될 예정인가요?
애널리스트들은 주식 평가를 내리기 위해 철저한 연구를 진행합니다. 이 연구에는 공개된 재무 보고서를 검토하고, Alnylam Pharmaceuticals의 경영진 및 고객과 대화하며, 실적 회의 통화를 듣는 것이 포함됩니다. 대부분의 애널리스트들은 이를 매 분기마다 수행하므로, 한 해에는 회사당 애널리스트 당 4번의 평가를 받을 수 있습니다. Alnylam Pharmaceuticals에 대한 마지막 평가는 7월 3, 2024에 제출되었으므로, 다음 평가가 7월 3, 2025쯤에 제공될 것으로 예상됩니다.
애널리스트 평가 Alnylam Pharmaceuticals (ALNY)가 올바른가요?
평가는 주관적이며 변할 수 있지만, 최신 Alnylam Pharmaceuticals (ALNY) 평가는 유지했다로, 가격 목표는 $160.00에서 $248.00으로 조정되었습니다. 현재 Alnylam Pharmaceuticals (ALNY)의 가격은 $251.03로, 이는 애널리스트의 예측 범위에서 out of입니다.
검색 애널리스트 평가 및 가격 목표 모든 주식에 대한
사람들이 또한 지켜본다
© 2024 Benzinga | All Rights Reserved